<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315636</url>
  </required_header>
  <id_info>
    <org_study_id>Surfactant nebulization</org_study_id>
    <nct_id>NCT04315636</nct_id>
  </id_info>
  <brief_title>Surfactant Nebulization for the Early Aeration of the Preterm Lung</brief_title>
  <acronym>SUNSET</acronym>
  <official_title>Surfactant Nebulization for the Early Aeration of the Preterm Lung: a Single Blinded, Parallel, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory distress syndrome is the most common cause of respiratory failure in preterm
      infants. Treatment consists of respiratory support and exogenous surfactant administration.
      Commonly, surfactant is administered via an endotracheal tube during mechanical ventilation.
      However, mechanical ventilation is considered an important risk factor for developing
      bronchopulmonary dysplasia.

      Surfactant nebulisation during noninvasive ventilation may offer an alternative method for
      surfactant administration and has been shown to be promising in terms of physiological as
      well as clinical changes. In preterm infants with respiratory distress syndrome, the effect
      of intratracheally administered surfactant on lung function during invasive ventilation has
      been studied extensively. However, the effect of early postnatal surfactant nebulization
      remains unclear.

      Therefore, the investigators plan to conduct a randomized controlled trial in order to
      investigate the effect of surfactant nebulization immediately after birth on early postnatal
      lung volume and short-term respiratory stability.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EIT: End-expiratory lung impedance (EELI)</measure>
    <time_frame>Between birth and 30 minutes of life.</time_frame>
    <description>Change in EELI using electrical impedance tomography (arbitrary units per kilogram)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EIT: End-expiratory lung impedance (EELI)</measure>
    <time_frame>At 6, 12, and 24 hours of life and at 36 weeks postmenstrual age</time_frame>
    <description>EELI using electrical impedance tomography (arbitrary units per kilogram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EIT: Regional ventilation distribution</measure>
    <time_frame>At 6, 12, and 24 hours of life and at 36 weeks postmenstrual age.</time_frame>
    <description>Regional ventilation distribution using electrical impedance tomography (arbitrary units per kilogram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EIT: Tidal volumes</measure>
    <time_frame>At 6, 12, and 24 hours of life and at 36 weeks postmenstrual age.</time_frame>
    <description>Tidal volumes using electrical impedance tomography (arbitrary units per kilogram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EIT: Association between EELI losses and SpO2/FiO2 ratio.</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>Association between the number of EELI losses &gt;50% and the SpO2/FiO2 ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EIT: Association between EELI losses and need/level of respiratory support.</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>Association between the number of EELI losses &gt;50% and the need/level of respiratory support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological: Heart rate</measure>
    <time_frame>For the first 30 minutes after birth, as well as at 6, 12, and 24 hours of life.</time_frame>
    <description>Continuous recording of heart rate (beats per minute).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological: Oxygen saturation (SpO2)</measure>
    <time_frame>For the first 30 minutes after birth, and at 6, 12, and 24 hours of life.</time_frame>
    <description>Continuous recording of SpO2 (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological: Fraction of inspired oxygen</measure>
    <time_frame>For the first 30 minutes after birth, and at 6, 12, and 24 hours of life.</time_frame>
    <description>Continuous recording of fraction of inspired oxygen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological: SpO2/FiO2 ratio</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>SpO2/FiO2 ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological: Body temperature</measure>
    <time_frame>In the delivery room.</time_frame>
    <description>Number of events with body temperature &lt;36.5 or &gt;37.5Â°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: Peak inspiratory pressure (PIP)</measure>
    <time_frame>During the first 30 minutes of life.</time_frame>
    <description>Continuous recording of PIP in the control group (cmH2O).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: Positive end-expiratory pressure (PEEP)</measure>
    <time_frame>During the first 30 minutes of life.</time_frame>
    <description>Continuous recording of PEEP in the control group (cmH2O).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: Tidal volume (Vt)</measure>
    <time_frame>During the first 30 minutes of life.</time_frame>
    <description>Continuous recording of Vt in the control group (cmH2O).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: PEEP (positive end-expiratory pressure)</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>PEEP during noninvasive and invasive ventilation [mbar]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: PIP (peak inspiratory pressure)</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>PIP during noninvasive and invasive ventilation [mbar]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory: Respiratory rate</measure>
    <time_frame>At 6, 12, and 24 hours of life.</time_frame>
    <description>Respiratory rate during noninvasive and invasive ventilation [breaths per minute]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Length and type of noninvasive respiratory support</measure>
    <time_frame>During the first 30 minutes of life.</time_frame>
    <description>Total length of CPAP/NIPPV support assessed retrospectively using video recordings (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Total time on noninvasive and invasive respiratory support</measure>
    <time_frame>Until 36 weeks postmenstrual age</time_frame>
    <description>Total time on invasive and noninvasive respiratory support (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Frequency and duration of facemask repositioning</measure>
    <time_frame>During the first 30 minutes after birth.</time_frame>
    <description>Frequency and duration of facemask repositioning assessed retrospectively using video recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Intubation</measure>
    <time_frame>At 24 and 72 hours of life, at 7 days of life. Until 36 weeks postmenstrual age.</time_frame>
    <description>Intubation rate (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Time to first intubation</measure>
    <time_frame>From birth until 36 weeks postmenstrual age.</time_frame>
    <description>Time to first intubation (days, minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Number of episodes of desaturation and bradycardia</measure>
    <time_frame>During the first 24 hours of life.</time_frame>
    <description>Number of episodes of desaturation (SpO2 &lt;80%) and bradycardia (&lt;80 beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Bronchopulmonary dysplasia (BPD)</measure>
    <time_frame>At 36 weeks postmenstrual age.</time_frame>
    <description>BPD, maximum grade [number of cases]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Intraventricular haemorrhage (IVH)</measure>
    <time_frame>At 36 weeks postmenstrual age.</time_frame>
    <description>IVH, maximum grade [number of cases]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Retinopathy of prematurity (ROP)</measure>
    <time_frame>At 36 weeks postmenstrual age.</time_frame>
    <description>ROP, maximum grade [number of cases]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Necrotizing enterocolitis (NEC)</measure>
    <time_frame>At 36 weeks postmenstrual age.</time_frame>
    <description>NEC, surgically treated [number of cases]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Blood-culture positive sepsis</measure>
    <time_frame>At 36 weeks postmenstrual age.</time_frame>
    <description>Blood-culture positive sepsis [number of cases]</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety: Death</measure>
    <time_frame>Until 36 weeks postmenstrual age.</time_frame>
    <description>Death [number of cases]</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety: Pulmonary haemorrhage</measure>
    <time_frame>Until 36 weeks postmenstrual age.</time_frame>
    <description>Pulmonary haemorrhage [number of cases]</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety: Air leak</measure>
    <time_frame>Until 36 weeks postmenstrual age.</time_frame>
    <description>Air leak [number of cases]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Surfactant Deficiency Syndrome Neonatal</condition>
  <arm_group>
    <arm_group_label>Surfactant nebulisation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfactant nebulisation</intervention_name>
    <description>200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).</description>
    <arm_group_label>Surfactant nebulisation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inborn

          -  gestational age at birth from 26 0/7 to 31 6/7 weeks

          -  written informed consent

        Exclusion Criteria:

          -  severe congenital malformation adversely affecting surfactant nebulisation or life
             expectancy

          -  a priori palliative care

          -  genetically defined syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Minutes</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christoph M Ruegger, MD</last_name>
    <phone>+41 43 253 98 10</phone>
    <email>christoph.rueegger@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk Bassler, MD</last_name>
    <phone>+41 44 255 53 45</phone>
    <email>dirk.bassler@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neonatology, University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph M Ruegger, MD</last_name>
      <email>christoph.rueegger@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Gaertner, MD</last_name>
      <email>vincent.gaertner@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Minocchieri S, Berry CA, Pillow JJ; CureNeb Study Team. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F313-F319. doi: 10.1136/archdischild-2018-315051. Epub 2018 Jul 26. Erratum in: Arch Dis Child Fetal Neonatal Ed. 2020 Mar;105(2):e1.</citation>
    <PMID>30049729</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

